<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861832</url>
  </required_header>
  <id_info>
    <org_study_id>R41MD012318-01</org_study_id>
    <nct_id>NCT03861832</nct_id>
  </id_info>
  <brief_title>SMART Brain Health in African-Americans</brief_title>
  <acronym>SMART</acronym>
  <official_title>A Systematic Medical Approach to Reward Transformation (SMART) for Brain Health in Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Howard University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Home Development Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Geneus Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Howard University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that opioid use in African-Americans will be associated with
      hypodopaminergic alleles that alter the threshold for activating feelings of reward and
      pleasure within the dopaminergic system, and that these allelic frequencies will differ
      significantly from European Americans. Planned is a targeted system to study genetic risks
      for reward deficiency using risk gene panel to assign a genetic addiction risk score (GARS),
      comprehensive surveys to determine quality of life and exposure to stressors and trauma. This
      system will allow prediction of addiction and relapse potential and delivery of personalized
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals seeking treatment for Opioid Use Disorder in the Washington DC metro area will be
      recruited to this Study, which consists of 1) early pre-disposition diagnosis using the
      Genetic Addiction Risk Score (GARS); 2) Assessment of reward deficiency, co-morbid
      neuropsychiatric disease, quality of life/happiness, stressors/trauma and other psychometric
      measurements using validated questionnaires; Urine drug testing during actual treatment that
      uses comprehensive analysis of reported drugs to determine compliance with prescription
      medications and non-abstinence to illicit drugs; and 4) adjunctive treatment with
      neuroadaptogen amino acid therapy (NAAT), a glutaminergic-dopaminergic optimization
      nutraceutical (generic name: KB220) compared to placebo, aimed to prevent relapse by
      induction of dopamine homeostasis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to one of two or more groups in parallel for the duration of the study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Relapse</measure>
    <time_frame>4 months</time_frame>
    <description>Number of times opioids and other types of drugs of abuse are detected in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic Testing for the number of risk alleles for Reward Genes through GARS</measure>
    <time_frame>Month 1</time_frame>
    <description>Number of reward gene variants in opioid use disorder patients compared to controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in assessment of depression, anxiety, PTSD</measure>
    <time_frame>4 months</time_frame>
    <description>Change from Baseline in from the Comprehensive Universal Behavioral Screen for depression, anxiety, PTSD, after 4 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Reward Deficiency Syndrome Questionnaire (RDSQ)</measure>
    <time_frame>4 months</time_frame>
    <description>Change in risky behaviors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Addiction Severity Index (ASI)</measure>
    <time_frame>4 months</time_frame>
    <description>Change in indices associated with addiction and associated behaviors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin B6 testing</measure>
    <time_frame>Month 4</time_frame>
    <description>Presence of B6 in blood to test for compliance with Nutraceutical</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Opioid Use Disorder</condition>
  <condition>Substance Use Disorders</condition>
  <condition>Dopamine Dysregulation Syndrome</condition>
  <condition>African Americans</condition>
  <arm_group>
    <arm_group_label>Nutraceutical, KB220Z</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A nutraceutical pill containing pro-dopamine precursors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo that looks the same and is in a similar bottle</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>KB220Z</intervention_name>
    <description>Acts to enhance dopamine</description>
    <arm_group_label>Nutraceutical, KB220Z</arm_group_label>
    <other_name>KB220</other_name>
    <other_name>Synaptamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be able to consent and understand questions being asked during surveys

          -  Must be willing to undergo pharmacogenetic testing

          -  Must be able to swallow tablets

        Exclusion Criteria:

          -  Clinical Diagnosis of Alzheimer's disease/Dementia

          -  Clinical Diagnosis of Schizophrenia

          -  Clinical Diagnosis of a terminal disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marjorie C. Gondré-Lewis, Ph.D.</last_name>
    <phone>202-806-5274</phone>
    <email>mgondre-lewis@Howard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beverlyn Settles-Reaves, Ph.D.</last_name>
    <phone>202-806-7707</phone>
    <email>bsettles-reaves@howard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie C. Gondré-Lewis, PhD</last_name>
      <phone>202-806-5274</phone>
      <email>mgondre-lewis@Howard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Beverlyn Settles-Reaves, Ph.D.</last_name>
      <phone>202-806-7707</phone>
      <email>bsettles-reaves@howard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tanya Alim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Home Development Group</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Howard University</investigator_affiliation>
    <investigator_full_name>Marjorie Gondre-Lewis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The genetic data will be shared when compiled</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>within 18 months following completion of the study, and the cleaning of clinical and genomic data</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

